Expanding the phenotypic spectrum of diabetic striatopathy: a case series
Objective: To illustrate the spectrum of diabetic striatopathy by presenting 3 cases with different clinical and neuroimaging findings. Background: Diabetic striatopathy is a rare complication…Persistent and efficient transduction of the putamen following gene therapy for aromatic L-amino acid decarboxylase deficiency
Objective: This study aimed to evaluate longitudinal transduction in subcortical regions and transduction of the cortico-putaminal network after putaminal AADC gene therapy. Background: Aromatic L-amino…Depression in various forms of parkinsonism and striatal hyperkinesis
Objective: To examine of the degree of depression in various forms of Parkinsonism and striatal hyperkinesis Background: Depression is the basis of affective disorders. Almost…Characterization of striatal dopaminergic neurotransmission in the rat pre-formed fibril models of Parkinson’s disease
Objective: To determine the longitudinal effects of synucleinopathy and synucleinopathy-triggered nigrostriatal degeneration on basal and evoked striatal dopamine (DA) release in the striatum at 4…Blood-Brain Barrier Opening with Focused Ultrasound in Parkinson´s Disease with Cognitive Impairment: A Safety and Feasibility Study
Objective: To evaluate the safety and feasibility of MR guided focused ultrasound (MRgFUS) blood-brain barrier (BBB) opening in the cortex or the striatum in Parkinson´s…Novel Recessive Mitochondrial Mutations Causing Leigh’s Syndrome and Movement Disorders
Objective: Describe discovery of novel mitochondrial mutations causing ataxia and dystonia syndromes with occurrence in childhood. Background: An African-American man at 5 years old subacutely…Striatal neurodegeneration in the presymptomatic phase of X-linked Dystonia-Parkinsonism
Objective: To identify structural brain changes in patients with X-linked dystonia-parkinsonism (XDP) and non-manifesting carriers of the TAF1 SVA retrotransposon insertion (NMC). Background: XDP is…Perillyl alcohol restores mitochondrial dysfunction and abridge NLRP3 inflammasomes activation in in-vitro and in-vivo model of Parkinson’s disease
Objective: Parkinson's disease (PD) affects around 2-3% population of age greater than 65 and is the second most common neurogenerative disorder. The molecular mechanism underpinning…Dopaminergic denervation in de-novo Parkinson’s disease. Does functional somatotopy plays a role?
Objective: To clarify how dopaminergic denervation occurs along the dorsoventral axis of the posterior putamen in the earliest stages of PD. Background: Dopamine loss in…7,8- Dihydroxyflavone prevents 3-NitropropionicAcid (3-NP)-induced Striatal Toxicity by Modulating the TrkB receptor and Microglial Activation Pathway
Objective: Hungtion’s disease (HD) is an autosomal governing neurodegenerative disorder caused by production of mutant hungtingtin(Htt) protein followed by death of the GABAergic neurons in…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 10
- Next Page »